En Es
Categories

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology. The company’s products detect multi-pathogens with high sensitivity, specificity and reproducibility, resulting in saving of time, labor and cos ...
Products Covid-19NewsSummary
Close

Covid-19 Seegene

Clinical Laboratory

SARS-CoV-2 Test
Allplex 2019-nCoV Assay

The Allplex 2019-nCoV Assay is a multiplex Real-time PCR assay for the simultaneous detection of three target genes of SARS-CoV-2 in a single tube. The assay is designed to detect RdRP and N genes specific for SARS-CoV-2, and E gene for all of Sarbecovirus, including SARS-CoV-2.
More details

SARS-CoV-2 Test
Allplex SARS-CoV-2 Assay

The Allplex SARS-CoV-2 Assay is a multiplex real-time PCR assay to detect four target genes of SARS-CoV-2, causing COVID-19 in a single tube. The assay is designed to detect RdRP, S and N genes specific for SARS-CoV-2, and E gene for all of Sarbecovirus including SARS-CoV-2. It can be applied on Seegene’s automated system that enables high throughput testing.
More details

SARS-CoV-2/FluA/FluB/RSV Test
Allplex SARS-CoV-2/FluA/FluB/RSV Assay

The Allplex SARS-CoV-2/Flu A/Flu B/RSV Assay is a multiplex real-time PCR assay designed to detect N gene, RdRP gene and S gene for SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) A/B in a single tube. The assay is applied on Seegene’s integrated All-in-One automated platform which enables high-throughput testing.
More details
Close

News of Seegene

Seegene Unveils Combination Test at ECCMID 2018

19 Apr 2018
Seegene Unveils Combination Test at ECCMID 2018
Seegene Inc., a developer of multiplex PCR technologies, introduced a combination test at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) held in Madrid, Spain, from April 21 to 24, 2018. The combination test is a high-efficiency solution that diagnoses various causes of diseases with multiplex molecular diagnosis assays. Seegene also showcased its molecular diagnostic system SGSTAR (Seegene Sameday Test and Report), which allows order-to-report on the same day and enables the running of the combination test.
Read More

Seegene Develops World’s First Multiplex MDx Assays with AI System

09 Jan 2018
Seegene Develops World’s First Multiplex MDx Assays with AI System
Seegene Inc., a developer of multiplex PCR technologies, successfully developed molecular diagnostics (MDx) assays in just four days using an artificial intelligence- (AI) based automated assay development system. These assays are high multiplex real-time PCR reagents developed completely by AI and are meant for the simultaneous detection of eight different DNA targets for each of meningitis and sexually transmitted infections.
Read More

Seegene Partners with Hamilton to Develop Random Access System

28 Sep 2017
Seegene Partners with Hamilton to Develop Random Access System
Seegene, a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx), has signed a Memorandum of Understanding (MoU) with Hamilton Company, which designs and manufactures precision measurement devices, automated liquid handling workstations, and sample management systems, to develop the Seegene Random Access System.
Read More

Seegene Collaborates with Thermo to Enter US Market

29 May 2017
Seegene Collaborates with Thermo to Enter US Market
Seegene Inc., a developer of multiplex molecular diagnostics technologies and assays, has entered into a collaboration with Thermo Fisher Scientific, in which Seegene will file for U.S. Food and Drug Administration (FDA) clearance of its Allplex diagnostic assay portfolio at the same time that Thermo Fisher files for FDA clearance to run Seegene's assays on Thermo Fisher's QuantStudio 5 Real-Time PCR System (PCR System).
Read More
Close

About Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology. The company’s products detect multi-pathogens with high sensitivity, specificity and reproducibility, resulting in saving of time, labor and cost.
FaceBook Twitter Google+ Linked in
SARS-CoV-2 Test

SARS-CoV-2 Test

Model: Allplex 2019-nCoV Assay
Request Information

Description:

The Allplex 2019-nCoV Assay is a multiplex Real-time PCR assay for the simultaneous detection of three target genes of SARS-CoV-2 in a single tube. The assay is designed to detect RdRP and N genes specific for SARS-CoV-2, and E gene for all of Sarbecovirus, including SARS-CoV-2.

Features

Features

• Multiplex real-time PCR - Detection and identification of target genes (E gene, RdRP gene, N gene) specific for COVID-19 in a single tube
• Short TAT - Results within 1 hour and 50 minutes after extraction
• Powerful performance - PCR with high sensitivity and specificity
• Proper patient care - Quick and proper treatment provided by accurate test results
• Automatic data analyzer - Automated data interpretation and LIS interlocking with Seegene Viewer
• Whole process validation - Whole process validation from extraction to PCR by whole process control
• User-friendly workflow - Convenient workflow using Seegene’s automated one platform Request Information

Send A Message To This Supplier

* Required Information
* Email
To
Seegene (SARS-CoV-2 Test)
* Message

Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions